Search

Displaying results 3051 - 3060 of 4207 in total
  1. Drug

    Amrinone

    go.drugbank.com/drugs/DB01427
    ApprovedWithdrawn

    Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

  2. Drug

    Chromic nitrate

    go.drugbank.com/drugs/DB14527
    Approved

  3. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted F...

  4. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    It was generated by HGS using the Abgenix XenoMouse technology.

  5. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  6. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797]

  7. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  8. Drug

    N-Methylmesoporphyrin

    go.drugbank.com/drugs/DB01911
    Experimental

    These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions by four methine groups to form a macrocyclic structure.

  9. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    It is being devloped by Intercell AG for the treatment of hepatitis C.

  10. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial.